Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern

Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern

Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent...

Full description

Bibliographic Details
Main Authors: Alehegn Gelaye, Abdallah Haidar, Christina Kassab, Syed Kazmi, Prabhat Sinha
Format: Article
Language:English
Published: Hindawi Limited 2016-01-01
Series:Case Reports in Critical Care
Online Access:http://dx.doi.org/10.1155/2016/1656182
id doaj-26a5805b4ba44d75b35a9989b2f415ee
record_format Article
spelling doaj-26a5805b4ba44d75b35a9989b2f415ee2020-11-25T01:07:42ZengHindawi LimitedCase Reports in Critical Care2090-64202090-64392016-01-01201610.1155/2016/16561821656182Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety ConcernAlehegn Gelaye0Abdallah Haidar1Christina Kassab2Syed Kazmi3Prabhat Sinha4Section of Pulmonary and Critical Care Medicine, Providence Hospital and Medical Center, 16001 W 9 Mile Road, Southfield, MI 48075, USADepartment of Internal Medicine, Providence Hospital and Medical Center, 16001 W 9 Mile Road, Southfield, MI 48075, USADepartment of Internal Medicine, Providence Hospital and Medical Center, 16001 W 9 Mile Road, Southfield, MI 48075, USASection of Pulmonary and Critical Care Medicine, Providence Hospital and Medical Center, 16001 W 9 Mile Road, Southfield, MI 48075, USASection of Pulmonary and Critical Care Medicine, Providence Hospital and Medical Center, 16001 W 9 Mile Road, Southfield, MI 48075, USACanagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent of insulin secretion or action. However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported. Prompt identification of the causal association and initiation of appropriate therapy should be instituted for this life threatening condition.http://dx.doi.org/10.1155/2016/1656182
collection DOAJ
language English
format Article
sources DOAJ
author Alehegn Gelaye
Abdallah Haidar
Christina Kassab
Syed Kazmi
Prabhat Sinha
spellingShingle Alehegn Gelaye
Abdallah Haidar
Christina Kassab
Syed Kazmi
Prabhat Sinha
Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
Case Reports in Critical Care
author_facet Alehegn Gelaye
Abdallah Haidar
Christina Kassab
Syed Kazmi
Prabhat Sinha
author_sort Alehegn Gelaye
title Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
title_short Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
title_full Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
title_fullStr Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
title_full_unstemmed Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
title_sort severe ketoacidosis associated with canagliflozin (invokana): a safety concern
publisher Hindawi Limited
series Case Reports in Critical Care
issn 2090-6420
2090-6439
publishDate 2016-01-01
description Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent of insulin secretion or action. However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported. Prompt identification of the causal association and initiation of appropriate therapy should be instituted for this life threatening condition.
url http://dx.doi.org/10.1155/2016/1656182
work_keys_str_mv AT alehegngelaye severeketoacidosisassociatedwithcanagliflozininvokanaasafetyconcern
AT abdallahhaidar severeketoacidosisassociatedwithcanagliflozininvokanaasafetyconcern
AT christinakassab severeketoacidosisassociatedwithcanagliflozininvokanaasafetyconcern
AT syedkazmi severeketoacidosisassociatedwithcanagliflozininvokanaasafetyconcern
AT prabhatsinha severeketoacidosisassociatedwithcanagliflozininvokanaasafetyconcern
_version_ 1725185837105152000

Similar Items